Citation Impact
Citing Papers
Comprehensive Assessment of Genetic and Molecular Features Predicting Outcome in Patients With Chronic Lymphocytic Leukemia: Results From the US Intergroup Phase III Trial E2997
2007
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia
2002 Standout
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
2009 Standout
Cancer statistics, 2022
2022 Standout
Cancer statistics, 2023
2023 Standout
Cancer statistics, 2020
2020 Standout
Cancer statistics, 2024
2024 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Cancer Statistics, 2021
2021 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Similar characteristics of the CDR3 of VH1‐69/DP‐10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells
1998
Guidelines on the use of therapeutic apheresis in clinical practice—Evidence‐based approach from the apheresis applications committee of the American Society for Apheresis
2010
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
Bcl‐2 regulatory pathway is functional in chronic lymphocytic leukemia
2004
Granulocyte-macrophage colony-stimulating factor associated with induction treatment of acute myelogenous leukemia: a randomized trial by the European Organization for Research and Treatment of Cancer Leukemia Cooperative Group.
1996
SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials
2013 Standout
Phase I study of the anti-CD40 humanized monoclonal antibody lucatumumab (HCD122) in relapsed chronic lymphocytic leukemia
2012
Role of AID in Tumorigenesis
2007 StandoutNobel
The global health burden of infection‐associated cancers in the year 2002
2006 Standout
Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia
2015
Comparison of ‘sequential’ versus ‘standard’ chemotherapy as re‐induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML‐R trial
2001
Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia
2002
Consort 2010 statement: extension to cluster randomised trials
2012 Standout
Evaluating treatment strategies in chronic lymphocytic leukemia
2001
The Toll-like receptor 2/1 (TLR2/1) complex initiates human platelet activation via the src/Syk/LAT/PLCγ2 signalling cascade
2013 StandoutNobel
Putting tumours in context
2001 Standout
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
2011 Standout
Apoptosis in cancer: from pathogenesis to treatment
2011 Standout
Targeting multidrug resistance in cancer
2006 Standout
Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission – experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG)
2004
Chemotherapy and the war on cancer
2005 Standout
Four deaths and a funeral: from caspases to alternative mechanisms
2001 Standout
Immunity, Inflammation, and Cancer
2010 Standout
Biology and management of relapsed acute myeloid leukaemia
2005
Platelets and the immune continuum
2011 Standout
Evidence based therapeutic apheresis in autoimmune and other hemolytic anemias
2007
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
2011 Standout
Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia
2000
Hematopoietic Stem-Cell Transplantation
2006 Standout
Due to low infection rates no routine anti‐infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine‐based first line therapy
2006
CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia
1999
Non-Hodgkin lymphoma
2012
The functions of thrombospondin-1 and-2
2000 Standout
Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin)
2002
The efficacy and safety of B‐cell depletion with anti‐CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura
2004
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
2006 Standout
The AID Dilemma
2012 StandoutNobel
A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia
2004
A Controlled Study of Recombinant Human Granulocyte Colony-Stimulating Factor in Elderly Patients after Treatment for Acute Myelogenous Leukemia
1995
A novel form of Epstein-Barr virus latency in normal B cells in vivo
1995 Standout
The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire
1994
Mitoxantrone
1996
Rituximab-Associated Infections
2010
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue
2019 Standout
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelines
2008 Standout
Fludarabine phosphate for the first-line treatment of chronic lymphocytic leukaemia
2009
Detection of Epstein-Barr virus by polymerase chain reaction
1990
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
2011 Standout
Acute Myeloid Leukemia
2015 Standout
The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells
2005 Standout
IDA‐FLAG (idarubicin, fludarabine, cytarabine, G‐CSF), an effective remission‐induction therapy for poor‐prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial
1998
Antitumor Antibiotics: Bleomycin, Enediynes, and Mitomycin
2005 Standout
The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders
1994
Issues in data monitoring and interim analysis of trials
2005
Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors
2002
Granulocyte Colony-Stimulating Factor (Filgrastim) Accelerates Granulocyte Recovery After Intensive Postremission Chemotherapy for Acute Myeloid Leukemia With Aziridinyl Benzoquinone and Mitoxantrone: Cancer and Leukemia Group B Study 9022
1997
Pentostatin, Cyclophosphamide, and Rituximab Is an Active, Well-Tolerated Regimen for Patients With Previously Treated Chronic Lymphocytic Leukemia
2006
Nitric oxide and the immune response
2001 Standout
Interleukin-6 dimers produced by endothelial cells inhibit apoptosis of B-chronic lymphocytic leukemia cells
2001
American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients
2006 Standout
Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies
2017 StandoutNobel
Evidence of Toll‐like receptor molecules on human platelets
2005
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
2008 Standout
Human Immunoglobulin M Memory B Cells Controlling Streptococcus pneumoniae Infections Are Generated in the Spleen
2003
Guidelines on the Use of Therapeutic Apheresis in Clinical Practice—Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Sixth Special Issue
2013
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Childbearing issues in breast carcinoma survivors
1997
Toward the potential cure of leukemias in the next decade
2018
Predictors of therapy-related leukemia and myelodysplasia following autologous transplantation for lymphoma: an assessment of risk factors
2000
Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia
1999 Standout
Screening for hyperglycaemia in pregnancy: a rapid update for the National Screening Committee
2010 StandoutNobel
Cancer treatment and survivorship statistics, 2016
2016 Standout
Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1
2002
Low-affinity IgM antibodies lacking somatic hypermutations are produced in the secondary response of C57BL/6 mice to (4-hydroxy-3-nitrophenyl)acetyl hapten
2013 StandoutNobel
Detection of Epstein-Barr virus genomes in Hodgkin's disease: relation to age.
1991
How I treat refractory and early relapsed acute myeloid leukemia
2015
Retrospective analysis of 30 severe autoimmune hemolytic anemia patients treated by whole blood exchange transfusion
2015
Cancer treatment and survivorship statistics, 2019
2019 Standout
Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia
1999
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
2005 Standout
Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL
2003
Unmutated Ig VH Genes Are Associated With a More Aggressive Form of Chronic Lymphocytic Leukemia
1999 Standout
Health-Related Quality of Life in Younger Patients With Chronic Lymphocytic Leukemia Treated With Fludarabine Plus Cyclophosphamide or Fludarabine Alone for First-Line Therapy: A Study by the German CLL Study Group
2007
How I treat autoimmune hemolytic anemias in adults
2010
Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl‐2
1997
Integrating Genetic Approaches into the Discovery of Anticancer Drugs
1997 StandoutScienceNobel
Select High-Risk Genetic Features Predict Earlier Progression Following Chemoimmunotherapy With Fludarabine and Rituximab in Chronic Lymphocytic Leukemia: Justification for Risk-Adapted Therapy
2005
Chemotherapeutic Options in Chronic Lymphocytic Leukemia: a Meta-analysis of the Randomized Trials
1999
Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Advanced Chronic Lymphocytic Leukemia
2005
CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials
2010 Standout
B-Cell Chronic Lymphocytic Leukemia Cells Express a Functional Inducible Nitric Oxide Synthase Displaying Anti-Apoptotic Activity
1998
Works of Philippe Travade being referenced
Plasma exchanges do not increase red blood cell transfusion efficiency in severe autoimmune hemolytic anemia: A retrospective case-control study
2006
Chlorambucil in Indolent Chronic Lymphocytic Leukemia
1998
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients
2001
High-Dose Therapy and Autologous Bone Marrow Transplantation in First Complete or Partial Remission for Poor Prognosis Hodgkin's Disease
1996
Detection of epstein‐barr viral genomes in lymph nodes of Hodgkin's disease patients
1990
Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial.
1995
Enteroviral Meningoencephalitis after Anti‐CD20 (Rituximab) Treatment
2003
Ex vivo expansion of CD34+/CD41+ late progenitors from enriched peripheral blood CD34+ cells
2000
Patient accrual and interim statistical analysis in long‐term randomized clinical trials: The French chronic lymphocytic leukemia CLL 80 protocol as a case study
1986
Isolated spleen agenesis: a rare cause of thrombocytosis mimicking essential thrombocythemia.
2000
B-cell chronic lymphocytic leukemia: present status and future directions. French Cooperative Group on CLL
1991
Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia
1991
B-ly-7, a monoclonal antibody reactive with hairy cell leukemia, also defines an activation antigen on normal CD8+ T cells [see comments]
1990
Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia.
1993
Molecular Evidence of Persistent Echovirus 13 Meningoencephalitis in a Patient with Relapsed Lymphoma after an Outbreak of Meningitis in 2000
2003